Browse by Research Project Code

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0

Mitchell, R. et al. (2018) Targeting BCR-ABL independent TKI resistance in chronic myeloid leukaemia by mTOR and autophagy inhibition. Journal of the National Cancer Institute, 110(5), pp. 467-478. (doi:10.1093/jnci/djx236) (PMID:29165716) (PMCID:PMC5946859)

Scott, M. T. et al. (2016) Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition. Cancer Discovery, 6(11), pp. 1248-1257. (doi:10.1158/2159-8290.CD-16-0263) (PMID:27630125)

Sinclair, A. et al. (2016) CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells. Blood, 128(3), pp. 371-383. (doi:10.1182/blood-2015-08-661785) (PMID:27222476) (PMCID:PMC4991087)

Karvela, M. et al. (2016) ATG7 regulates energy metabolism, differentiation and survival of Philadelphia chromosome-positive cells. Autophagy, 12(6), pp. 936-948. (doi:10.1080/15548627.2016.1162359) (PMID:27168493) (PMCID:PMC4922442)

Holyoake, T. L. and Helgason, G. V. (2015) Do we need more drugs for chronic myeloid leukemia? Immunological Reviews, 263(1), pp. 106-123. (doi:10.1111/imr.12234) (PMID:25510274)

Klionsky, D. J. et al. (2014) Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 8(4), pp. 445-544. (doi:10.4161/auto.19496) (PMID:22966490) (PMCID:PMC3404883)

Karvela, M., Helgason, G. V. and Holyoake, T. L. (2012) Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Expert Review of Anticancer Therapy, 12(3), pp. 381-392. (doi:10.1586/ERA.12.10)

Hamilton, A. et al. (2012) Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood, 119(6), pp. 1501-1510. (doi:10.1182/blood-2010-12-326843)

Helgason, G. V. , Karvela, M. and Holyoake, T. L. (2011) Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood, 118(8), pp. 2035-2043. (doi:10.1182/blood-2011-01-330621)

Mukhopadhyay, A., Helgason, G. V. , Karvela, M. and Holyoake, T. L. (2011) Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon? Expert Review of Hematology, 4(4), pp. 369-371. (doi:10.1586/ehm.11.34)

Pellicano, F., Simara, P., Sinclair, A., Helgason, G.V. , Copland, M. , Grant, S. and Holyoake, T.L. (2011) The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells. Leukemia, 25(7), pp. 1159-67. (doi:10.1038/leu.2011.67)

Schemionek, M. et al. (2010) BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood, 115(16), pp. 3185-3195. (doi:10.1182/blood-2009-04-215376)

Allan, E.K., Hamilton, A., Hatziieremia, S., Zhou, P., Jorgensen, H.G., Vigneri, P. and Holyoake, T.L. (2009) Nuclear entrapment of BCR-ABL by combining imatinib mesylate with leptomycin B does not eliminate CD34+ chronic myeloid leukaemia cells. Leukemia, 23(5), pp. 1006-1008. (doi:10.1038/leu.2008.367)

Bellodi, C. et al. (2009) Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells. Journal of Clinical Investigation, 119(5), pp. 1109-1123. (doi:10.1172/JCI35660)

Hamilton, A., Alhashimi, F., Myssina, S., Jorgensen, H. G. and Holyoake, T. L. (2009) Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells. Experimental Hematology, 37(3), pp. 395-401. (doi:10.1016/j.exphem.2008.11.005)

Myssina, S. et al. (2009) Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells. Experimental Hematology, 37(2), pp. 206-214. (doi:10.1016/j.exphem.2008.10.013)

This list was generated on Thu Dec 12 17:03:19 2019 GMT.